The two companies intend to leverage their complementary expertise and technology to bring a novel long acting injectable and drug product manufacturing platform to market.
Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, using Persist’s AI-based formulation technology and Nivagen’s manufacturing capabilities. The collaboration aims to simplify and accelerate the development and approval of LAI drugs, which can provide sustained and controlled release of drugs over weeks or months, improving patient adherence and outcomes.
“We are excited to partner with Nivagen, a leading Pharmaceutical company with extensive experience and expertise in manufacturing and distributing pharmaceutical products. Together, we will leverage our AI-driven formulation platform to create a novel and scalable manufacturing process for long-acting injectables, which have the potential to transform the treatment of chronic diseases and improve patient quality of life,” said Karthik Raman, CEO of Persist AI.
“We are delighted to collaborate with Persist AI, a pioneer in AI-based formulation development for drug delivery systems. Our Sacramento, CA facility is equipped with robotic lines using Isolator technology to produce sterile drug products in IV bags (both aseptically and terminally sterilized), vials, syringes, and cartridges. Persist’s new technology will enhance our capabilities to handle complex injectables like long-acting injectables at our new manufacturing site. We believe that their technology can significantly reduce the time and cost of developing and producing long-acting injectables, which are a growing and underserved market. We look forward to combining our manufacturing capabilities and distribution network with their innovative technology to bring a new and differentiated product to market,” said Jay Shukla, CEO of Nivagen.
iPhone or Android? Your Smartphone Choice May Be More About Habit Than Brain Wiring By…
FDA Approves Priovant’s Lisraya for Rare Autoimmune Skin and Muscle Disease Roivant-backed therapy becomes the…
FDA Greenlights Revolution Medicines’ Pancreatic Cancer Gamechanger By PharmaDesk International | JaanoAndSeekho.in August 28, 2026…
SHIKHA SURANA “I Will Not Let Age Change Me. I Will Change the Way I…
HARITHA The Power of Consistency — Building Strength One Rep at a Time Fitness |…
Fit at 48: Arita Shrivastava — Redefining Strength, Fitness and Confidence After 40 💪✨ Age…